Clinical Endpoint Bioequivalence study [Regulatives / Guidelines]

posted by sury – India, 2019-04-09 06:19 (901 d 00:19 ago) – Posting: # 20133
Views: 2,172

» You're referring to the draft guidance on miconazole buccal tablets, right ? Would be easier for us if you could say so straight away and link the guidance...

yes, i am actually referring to the miconazole buccal tablets drug

» For the statistical analysis the draft guidance refers to another draft guidance, on adapalene + benzoyl peroxyde. Did you read it ? Did you see anywhere a mention of log-transformation ? And why are you changing acceptance limits of -0.20 to +0.20 into 80.00 - 120.00 ?

There is no where in the draft guidance on what data (Untransformed and Log Transformed) to conduct the statistical Analysis.

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

 Admin contact
21,699 posts in 4,537 threads, 1,542 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Sunday 06:39 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz